Kairos Pharma Ltd. (NYSE American: KAPA) has announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide for patients with metastatic castration-resistant prostate cancer. The analysis revealed a statistically significant improvement in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving the combination compared to just two months for those receiving apalutamide alone (P=0.0008). This striking difference underscores the potential of ENV-105 to address a critical unmet need in prostate cancer treatment.
The implications of these findings are substantial. Metastatic castration-resistant prostate cancer is an advanced stage where standard therapies often fail, leading to rapid disease progression and poor outcomes. The dramatic PFS benefit observed with ENV-105 suggests that targeting CD105, a protein implicated in drug resistance and immune suppression, could reverse resistance to androgen receptor signaling inhibitors like apalutamide. If confirmed in later trials, this approach could significantly extend the time patients live without disease progression, delaying the need for more toxic treatments and improving quality of life.
In response to the interim data, Kairos Pharma has amended the Phase 2 protocol to enroll patients earlier in their disease course. Specifically, patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor will now be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. This change is designed to expand the eligible patient population and facilitate enrollment, with completion of the trial targeted for the fourth quarter of 2027 or earlier. By intervening earlier, the company hopes to maximize the benefit of ENV-105 and gather more robust data to support future regulatory submissions.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression. Its lead candidate, ENV-105, is an antibody that targets CD105, a key driver of resistance and relapse in response to standard therapy. By reversing drug resistance, ENV-105 aims to restore the effectiveness of existing treatments across multiple cancer types, potentially transforming the treatment landscape.
For investors and the biotech community, these results highlight Kairos Pharma's potential to deliver a novel therapy that could capture a significant share of the prostate cancer market. The company's focus on overcoming resistance mechanisms positions it well in the competitive oncology space. The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. To view the full press release, visit https://ibn.fm/EDpxx.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. Through InvestorWire, it provides access to a vast network of wire solutions and editorial syndication to 5,000+ outlets, ensuring that important developments like this reach a wide audience. For more information, visit BioMedWire. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
